FDA Foreign Facility Inspections: Expanded Unannounced Checks
- The Food and Drug Governance (FDA) is set to broaden its unannounced inspection program at foreign manufacturing facilities.
- Makary said the move ends a double standard where foreign companies received advance notice of inspections, unlike American manufacturers.
- The FDA will also revise its policies to prevent investigators from accepting travel accommodations, such as lodging and transportation, from the industry.
The FDA is substantially increasing unannounced inspections of foreign manufacturing facilities to safeguard the safety of food, drugs, and medical products entering the U.S.marketplace. This expansion,a key move to equalize oversight,addresses past practices where foreign firms often received advance notice,unlike their domestic counterparts. These surprise visits, part of a pilot program, aim to expose violations and ensure that companies adhere to rigorous standards. The FDA will also revise policies to prevent investigator travel accommodations, strengthening inspection integrity. With this shift towards more unexpected inspections, the agency authorized to act on those who delay or deny the process sends a strong message. For insights into these regulatory changes, explore the latest updates from News Directory 3. Discover what’s next as the FDA strengthens its enforcement strategy.
FDA Expands Unannounced Foreign Inspections for Enhanced Safety
Updated May 6, 2025
The Food and Drug Governance (FDA) is set to broaden its unannounced inspection program at foreign manufacturing facilities. The goal is to ensure that companies producing foods, essential medicines, and other medical products for U.S. consumers face the same rigorous oversight as their domestic counterparts. This expansion builds on a pilot program in India and China.
FDA Commissioner Martin A. Makary said the move ends a double standard where foreign companies received advance notice of inspections, unlike American manufacturers. He called it a key step in getting foreign inspections back on track.
The FDA will also revise its policies to prevent investigators from accepting travel accommodations, such as lodging and transportation, from the industry. This aims to maintain the integrity of the inspection process.
Currently, the FDA conducts about 12,000 domestic and 3,000 foreign inspections annually across more than 90 countries.While U.S. manufacturers face frequent, unannounced visits, foreign firms frequently enough have weeks to prepare. Despite this advance notice, the FDA has found serious deficiencies more than twice as often during foreign inspections.
The FDA said pre-announced domestic inspections are limited to specific programs and cases to ensure records and personnel are available. Companies cannot negotiate the timing of these inspections,and foreign firms should not have that ability either.
The agency said unannounced inspections will help expose those who falsify records or conceal violations, protecting American lives. The FDA is authorized to take action against firms that delay, deny, or limit inspections.
“The FDA’s rigorous, science-based global inspections of manufacturing facilities ensure that the food and drug products that enter the U.S. marketplace,and the homes of American consumers,are safe,trusted,and accessible,” said FDA Assistant Commissioner for Inspections and Investigations Michael Rogers.
Rogers added that these inspections provide real-time evidence for making fact-based regulatory decisions to protect public health. The FDA’s global inspections provide intelligence that strengthens enforcement and keeps American families safe. Every inspection undergoes a classification assignment process to enable an appropriate regulatory response.
What’s next
The FDA’s expanded approach marks a new era in enforcement, aimed at stronger and smarter support for public health and safety.